☆ 4.7 Article

Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)

DIABETES CARE (2022)

Related references

Note: Only part of the references are listed.

Article Endocrinology & Metabolism

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022

Summary: The American Diabetes Association's Standards of Medical Care in Diabetes provide clinical practice recommendations, treatment goals, and tools for evaluating quality of care for diabetes patients. The standards are regularly updated by a multidisciplinary expert committee and feedback from readers is welcome.

DIABETES CARE (2022)

Add to Collection

Article Endocrinology & Metabolism

10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022

Summary: The American Diabetes Association provides clinical practice recommendations and evaluation tools through the Diabetes Standards of Medical Care. The standards are updated annually or more frequently by a multidisciplinary committee.

DIABETES CARE (2022)

Add to Collection

Editorial Material Endocrinology & Metabolism

Introduction: Standards of Medical Care in Diabetes-2022

DIABETES CARE (2022)

Add to Collection

Article Endocrinology & Metabolism

7. Diabetes Technology: Standards of Medical Care in Diabetes-2022

Summary: The American Diabetes Association (ADA) Standards of Medical Care in Diabetes provide clinical practice recommendations, treatment goals, and evaluation tools. The standards are updated by a professional committee and include a detailed introduction and evidence grading system.

DIABETES CARE (2022)

Add to Collection

Article Endocrinology & Metabolism

5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes-2022

Summary: The American Diabetes Association (ADA) Standards of Medical Care in Diabetes is a set of clinical practice recommendations that provides guidelines and evaluation tools for diabetes care. It is updated annually by the ADA Professional Practice Committee, and readers are invited to comment on the standards on the professional website.

DIABETES CARE (2022)

Add to Collection

Article Endocrinology & Metabolism

11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022

Summary: The American Diabetes Association (ADA) Standards of Medical Care in Diabetes provide comprehensive guidelines and tools for diabetes care. These standards are regularly updated by a professional committee to ensure their relevance and accuracy.

DIABETES CARE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

Rajiv Agarwal et al.

Summary: The study found that finerenone can reduce the risk of kidney disease and cardiovascular events in patients with type 2 diabetes. Screening patients for albuminuria can help reduce the burden of cardiovascular and kidney disease.

EUROPEAN HEART JOURNAL (2022)

Add to Collection

Article Urology & Nephrology

Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial

Rajiv Agarwal et al.

Summary: The study reveals that treatment with finerenone is associated with an increased risk of hyperkalemia, but routine monitoring and management strategies can mitigate its impact.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis

Victor Razuk et al.

Summary: SGLT-2 inhibitors improve cardiovascular outcomes regardless of heart failure history or left ventricular ejection fraction.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)

Add to Collection

Article Urology & Nephrology

A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease

Cynthia Delgado et al.

Summary: The National Kidney Foundation and the American Society of Nephrology have made recommendations regarding the consideration of race in GFR estimation. They suggest implementing the CKD-EPI creatinine equation without the race variable in all US laboratories and promoting the use of cystatin C for more accurate estimation. They also encourage research on new filtration markers and interventions to eliminate racial disparities. The unified approach should be adopted nationwide.

AMERICAN JOURNAL OF KIDNEY DISEASES (2022)

Add to Collection

Review Urology & Nephrology

KDIGO 2022 CLINICAL PRACTICE GUIDELINE FOR DIABETES MANAGEMENT IN CHRONIC KIDNEY DISEASE

Ian H. de Boer et al.

Summary: The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) is a focused update of the 2020 guideline, providing treatment recommendations for clinicians treating diabetes and CKD based on systematic reviews of relevant studies.

KIDNEY INTERNATIONAL (2022)

Add to Collection

Article Urology & Nephrology

Integrating Patient Priorities with Science by Community Engagement in the Kidney Precision Medicine Project

Katherine R. Tuttle et al.

Summary: The KPMP is a multisite study aimed at improving understanding of CKD and AKI caused by diabetes or hypertension through deep phenotyping. Patients and clinicians are actively involved in the Community Engagement Committee, guiding research priorities and ensuring alignment with patient interests. This partnership has set new benchmarks for patient leadership in precision medicine research.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Article Urology & Nephrology

The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Michael G. Shlipak et al.

Summary: Chronic kidney disease (CKD) is a significant global burden associated with higher morbidity and mortality, especially among individuals with lower socioeconomic status. Despite the availability of guidelines for evaluating and managing early CKD, there is still a lack of consensus on prioritizing early identification and intervention for CKD without incentives or quality measures.

KIDNEY INTERNATIONAL (2021)

Add to Collection

Editorial Material Urology & Nephrology

The Patient Voice in Health Care Decision Making The Perspective of People Living with Diabetes and CKD

Tami Sadusky et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Editorial Material Urology & Nephrology

SGLT2 Inhibitors in Diabetic Kidney Disease

Sophia Zoungas et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Editorial Material Urology & Nephrology

Rationale and design of the Kidney Precision Medicine Project

Ian H. de Boer et al.

Summary: The Kidney Precision Medicine Project aims to characterize kidney diseases at a molecular level, identify disease subgroups, and discover novel therapies. This multicenter study involves obtaining kidney biopsies, creating a kidney tissue atlas, and conducting in-depth analysis to improve understanding of chronic and acute kidney diseases. Participants will be followed for 10 years to track clinical outcomes, and all data will be made available for broad use by researchers, clinicians, and patients.

KIDNEY INTERNATIONAL (2021)

Add to Collection

Review Urology & Nephrology

KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease Abstracts

[Anonymous]

KIDNEY INTERNATIONAL (2021)

Add to Collection

Review Endocrinology & Metabolism

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Naveed Sattar et al.

Summary: The meta-analysis showed that GLP-1 receptor agonists can reduce the risk of major adverse cardiovascular events, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes, regardless of structural homology.

LANCET DIABETES & ENDOCRINOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US

Lauren A. Eberly et al.

Summary: This study showed that Black and female patients as well as those with low socioeconomic status were less likely to receive SGLT2 inhibitor treatment among patients with type 2 diabetes in the US.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Endocrinology & Metabolism

Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 US Health Care Organizations

Nikita Stempniewicz et al.

Summary: The study found that eGFR testing rates are generally high among people with type 2 diabetes in the U.S., but testing rates for uACR are suboptimal and vary significantly across different organizations and clinical practice sites. Increasing guideline-recommended uACR testing could enhance the detection of chronic kidney disease (CKD) in this population.

DIABETES CARE (2021)

Add to Collection

Article Peripheral Vascular Disease

Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers A Multinational Cohort Study

RuiJun Chen et al.

Summary: In a large-scale observational study, it was found that ARBs do not significantly differ in effectiveness compared to ACE inhibitors as first-line treatment for hypertension, but present a better safety profile. This supports the preferential prescription of ARBs over ACE inhibitors when initiating treatment for hypertension.

HYPERTENSION (2021)

Add to Collection

Article Urology & Nephrology

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

Glenn M. Chertow et al.

Summary: Among patients with stage 4 CKD and albuminuria, treatment with dapagliflozin showed consistent positive effects in reducing the risk of kidney failure, cardiovascular events, and mortality. The decline in eGFR was slower in the dapagliflozin group compared to placebo. Patients in both groups had similar rates of adverse events, indicating no increased risks associated with dapagliflozin treatment.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

Bertram Pitt et al.

Summary: Finerenone therapy improved cardiovascular outcomes in patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, compared to placebo. The risk of the primary outcome event was significantly lower in the finerenone group, primarily driven by a reduction in hospitalization for heart failure.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

Hertzel C. Gerstein et al.

Summary: The trial compared the cardiovascular and renal outcomes of weekly injections of efpeglenatide versus a placebo in participants with type 2 diabetes and a history of cardiovascular disease or current kidney disease. The study found that the risk of cardiovascular events was lower with efpeglenatide treatment, and a composite renal outcome event was also reduced.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Race, Genetic Ancestry, and Estimating Kidney Function in CKD

C. Hsu et al.

Summary: The study found that using serum creatinine levels to estimate GFR without taking race (or genetic ancestry) into account led to systematic misclassification. Estimating GFR with cystatin C produced similar results while eliminating negative consequences of race-based approaches.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials

Natalie Staplin et al.

Summary: SGLT-2 inhibitors show consistent relative effects across different patient groups, significantly reducing cardiovascular risk, progression of kidney disease, and risk of mortality. However, there is an increased risk of ketoacidosis and urinary tract infections, especially among patients with diabetes.

ECLINICALMEDICINE (2021)

Add to Collection

Article Endocrinology & Metabolism

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial

M. Angelyn Bethel et al.

DIABETES CARE (2020)

Add to Collection

Article Endocrinology & Metabolism

Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition

Rhys Williams et al.

DIABETES RESEARCH AND CLINICAL PRACTICE (2020)

Add to Collection

Editorial Material Urology & Nephrology

Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study

Raymond R. Townsend et al.

KIDNEY INTERNATIONAL (2020)

Add to Collection

Article Urology & Nephrology

CKD Awareness Among US Adults by Future Risk of Kidney Failure

Chi D. Chu et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2020)

Add to Collection

Article Endocrinology & Metabolism

Health Care Costs Associated With Macrovascular, Microvascular, and Metabolic Complications of Type 2 Diabetes Across Time: Estimates From a Population-Based Cohort of More Than 0.8 Million Individuals With Up to 15 Years of Follow-up

Hsuan-Ying Chen et al.

DIABETES CARE (2020)

Add to Collection

Article Endocrinology & Metabolism

The Impact of Cardiovascular Disease and Chronic Kidney Disease on Life Expectancy and Direct Medical Cost in a 10-Year Diabetes Cohort Study

Eric Yuk Fai Wan et al.

DIABETES CARE (2020)

Add to Collection

Editorial Material Urology & Nephrology

FOREWORD

Alison Steiber et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2020)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J. L. Heerspink et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

George L. Bakris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Urology & Nephrology

Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2 Subgroup Analysis of the Randomized CREDENCE Trial

George Bakris et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)

Add to Collection

Article Urology & Nephrology

Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN) Phase 3 Randomized Controlled Clinical Trial

Sadayoshi Ito et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)

Add to Collection

Article Endocrinology & Metabolism

Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus

Thea Anine Strom Halden et al.

DIABETES CARE (2019)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

V. Perkovic et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein et al.

LANCET (2019)

Add to Collection

Review Medicine, General & Internal

Chronic Kidney Disease Diagnosis and Management: A Review

Teresa K. Chen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

Add to Collection

Article Physiology

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus

Moritz Mahling et al.

KIDNEY & BLOOD PRESSURE RESEARCH (2019)

Add to Collection

Review Pharmacology & Pharmacy

Appraisal of Non-Cardiovascular Safety for Sodium-Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials

Fang-Hong Shi et al.

FRONTIERS IN PHARMACOLOGY (2019)

Add to Collection

Review Endocrinology & Metabolism

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

Brendan L. Neuen et al.

LANCET DIABETES & ENDOCRINOLOGY (2019)

Add to Collection

Article Surgery

Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety

Elisabeth Schwaiger et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2019)

Add to Collection

Article Immunology

Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases

Nizar Attallah et al.

TRANSPLANTATION PROCEEDINGS (2019)

Add to Collection

Article Transplantation

Efficacy and Safety of Empagliflozin in the Management of Diabetes Mellitus in Heart Transplant Recipients

Matthew G. Cehic et al.

TRANSPLANTATION DIRECT (2019)

Add to Collection

Editorial Material Medicine, General & Internal

Individualizing Blood Pressure Targets for People With Diabetes and Hypertension Comparing the ADA and the ACC/AHA Recommendations

Ian H. de Boer et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

Add to Collection

Article Endocrinology & Metabolism

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

Katherine R. Tuttle et al.

LANCET DIABETES & ENDOCRINOLOGY (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Results From the LEADER Trial

Johannes F. E. Mann et al.

CIRCULATION (2018)

Add to Collection

Article Endocrinology & Metabolism

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J. Davies et al.

DIABETES CARE (2018)

Add to Collection

Article Medicine, General & Internal

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez et al.

LANCET (2018)

Add to Collection

Review Medicine, General & Internal

Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy

Adeera Levin et al.

LANCET (2017)

Add to Collection

Article Medicine, General & Internal

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

Rury R. Holman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Liraglutide and Renal Outcomes in Type 2 Diabetes

Johannes F. E. Mann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

News Item Endocrinology & Metabolism

American Diabetes Association Standards of Medical Care in Diabetes 2017

Payal H. Marathe et al.

JOURNAL OF DIABETES (2017)

Add to Collection

Article Endocrinology & Metabolism

Diabetes and Hypertension: A Position Statement by the American Diabetes Association

Ian H. de Boer et al.

DIABETES CARE (2017)

Add to Collection

Article Endocrinology & Metabolism

Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in US Integrated Health Care Delivery Systems: 2005-2011

Ram D. Pathak et al.

DIABETES CARE (2016)

Add to Collection

Article Medicine, General & Internal

Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014

Maryam Afkarian et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

Add to Collection

Article Medicine, General & Internal

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Steven P. Marso et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

Marc A. Pfeffer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Review Medicine, General & Internal

Metformin in Patients With Type 2 Diabetes and Kidney Disease A Systematic Review

Silvio E. Inzucchi et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)

Add to Collection

Article Urology & Nephrology

The accuracy of predicting cardiovascular death based on one compared to several albuminuria values

Gudrun Hatlen et al.

KIDNEY INTERNATIONAL (2014)

Add to Collection

Review Urology & Nephrology

KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient

Christoph Wanner et al.

KIDNEY INTERNATIONAL (2014)

Add to Collection

Article Medicine, General & Internal

Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline

Paul E. Stevens et al.

ANNALS OF INTERNAL MEDICINE (2013)

Add to Collection

Article Urology & Nephrology

Kidney Disease and Increased Mortality Risk in Type 2 Diabetes

Maryam Afkarian et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)

Add to Collection

Article Medicine, General & Internal

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis

Caroline S. Fox et al.

LANCET (2012)

Add to Collection

Article Medicine, General & Internal

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

Colin Baigent et al.

LANCET (2011)

Add to Collection

Article Cardiac & Cardiovascular Systems

Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

C. Baigent et al.

AMERICAN HEART JOURNAL (2010)

Add to Collection

Article Medicine, General & Internal

Optimizing Insulin Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus: Optimal Dosing and Timing in the Outpatient Setting

Allison J. Hahr et al.

DM DISEASE-A-MONTH (2010)

Add to Collection

Article Medicine, General & Internal

A New Equation to Estimate Glomerular Filtration Rate

Andrew S. Levey et al.

ANNALS OF INTERNAL MEDICINE (2009)

Add to Collection

Article Medicine, General & Internal

Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis

Bengt C. Fellstroem et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Add to Collection

Article Physiology

Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): Demographic and baseline characteristics

C Wanner et al.

KIDNEY & BLOOD PRESSURE RESEARCH (2004)

Add to Collection

Article Urology & Nephrology

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study

WF Keane et al.

KIDNEY INTERNATIONAL (2003)

Add to Collection

Article Medicine, General & Internal

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

BM Brenner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.